High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: Still the standard

Oncology

Volumn 25, Issue 5, 2011, Pages

  Dutcher, Janice P ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERLEUKIN 2;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORPHOLOGY; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; GERM CELL TUMOR; HUMAN; IMMUNOREGULATION; IMMUNOSTIMULATION; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOMA; MELANOMA; METASTASIS; MOLECULAR DYNAMICS; PATIENT IDENTIFICATION; PATIENT SELECTION; PREDICTION; PROGRESSION FREE SURVIVAL; SOLID TUMOR; STANDARD; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

EID: 79956222196     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127-32.
2. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133-41
3. Atkins MB Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008;26:5748-54.
4. McDermott DF, Ghebremichael MS, Signoretti S, et al. The high-dose aldesleukin (HD IL-2) SELECT trial in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2010;28:15S:345s. (abst 4514)